NK-521

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameNK-521
Drug Alias NameNK521NK-521
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Gene therapy > Gene editing
Mechanisms of ActionNatural killer cell replacementsT cell immunoglobulin and ITIM domains modulatorsNK cell lectin-like receptor subfamily C member 1 modulators +[4] 
TargetsT cell immunoglobulin and ITIM domainsNK cell lectin-like receptor subfamily C member 1Transforming growth factor beta receptors
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBase Therapeutics (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBase Therapeutics (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A